Lauren Sciences LLC independently recognized as a Leading Drug Delivery Company, and its V-Smart Platform selected as a Significant Advance in BBB Technology, by Datamonitor Healthcare

October 22, 2012

New York, N.Y., October 22, 2012 -- Lauren Sciences LLC, a privately-held biotechnology company furthering development of its new V-Smart™ nanovesicle platform technology, announced today that it has been independently recognized as a leading drug delivery company, and its V-Smart™ platform selected as a significant advance in blood brain barrier (BBB) technology, by Datamonitor Healthcare.

Datamonitor Healthcare (part of Informa plc), a leading provider of online database and analysis services for the Pharmaceuticals and Healthcare industries, has just published the report "Central Nervous System Drug Delivery Specialists" in which Lauren Sciences LLC is identified as one of the leading drug delivery companies with innovative technologies designed to enhance central nervous system (CNS) drug delivery, one of only 15 companies chosen for inclusion in the report and selected to be profiled.

Datamonitor Healthcare has also identified Lauren Sciences' V-Smart™ technology as exemplifying significant recent advances in BBB technology, one of only four chosen as innovative technologies that enhance the penetration of CNS drugs, for inclusion in the report "Delivery Across the Blood-Brain Barrier" and selected to be highlighted as a case study.

"The inclusion of Lauren Sciences in the Datamonitor Healthcare reports can be justifiably claimed as independent acknowledgement of the important potential of Lauren Sciences and our V-Smart™ drug delivery technology," said Susan Rosenbaum, J.D., Chairman and Chief Executive Officer of Lauren Sciences. "We expect that this recognition will foster new research collaborations in the healthcare industry for Lauren Sciences and, thus, further development of our novel 'quick-to-clinic' V-Smart™ therapeutics for CNS-disease patients."
-end-
About the V-Smart™ Platform

V-Smart™ is a platform technology that can be used for a variety of applications, including delivery of therapeutic drugs. The V-Smart™ drug delivery system is based on novel nanovesicles that have advantages over other nanovesicles, such as liposomes. Major features of the V-Smart™ vesicles include: high stability, large encapsulation capacity, ability to carry many kinds of drugs across the BBB following systemic delivery, potential targeting capability and controlled release of encapsulated drugs at specific target sites.

About Lauren Sciences LLC


Lauren Sciences LLC is a privately-held biotechnology company focused on using its V-Smart™ platform to create a robust pipeline of V-Smart™ therapeutics, including CNS-active drugs that normally do not cross the BBB. The company's lead programs are for the treatment of: Parkinson's disease (funded with the award of a grant from The Michael J. Fox Foundation); neuro-HIV (funded with the award of a grant from The Campbell Foundation) and other CNS disorders, such as Alzheimer's, GBM (brain cancer) and ALS (Lou Gehrig's disease). The company's Chief Scientific Officer, Dr. Eliahu Heldman, is Professor Emeritus at Ben-Gurion University, Israel where he, with Drs. Sarina Grinberg and Charles Linder, developed the V-Smart™ technology and lead the Lauren Sciences research team. Dr. Irwin Hollander serves as the company's Vice President of Research and Development in New York.

Disclaimer


Datamonitor Healthcare is an independent organization that provides clients with unbiased expert analysis and in-depth forecasts for the pharmaceutical and healthcare markets. Profiled companies are selected purely by Datamonitor Healthcare's independent assessment of their importance in the market under discussion. They alone decided that Lauren Sciences was worthy of inclusion in their report on specialists, and that V-Smart™ would be one of the main case studies in their strategies report. Lauren Sciences did not approach Datamonitor Healthcare, had no influence or involvement in the decision or choice as to its inclusion and did not, and does not, receive any compensation therefor. Lauren Sciences LLC has not read the aforementioned reports and, therefore, cannot defend, or opine on, the contents therein.

Contact: Susan Rosenbaum, J.D., Lauren Sciences LLC, (917) 397-2826, info@laurensciences.com.

Lauren Sciences LLC

Related Drug Delivery Articles from Brightsurf:

Modelling microswimmers for drug delivery
An international group of theoretical physicists led by Abdallah Daddi-Moussa-Ider from Düsseldorf, Germany, has modelled the motion of microscopic, motile bodies - either powered micro-machines or living cells - in viscous liquid drops, using the Navier-Stokes equations.

Millimetre-precision drug delivery to the brain
Focused ultrasound waves help ETH researchers to deliver drugs to the brain with pinpoint accuracy, in other words only to where their effect is desired.

New smart drug delivery system may help treatment for neurological disorders
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.

Novel drug delivery particles use neurotransmitters as a 'passport' into the brain
Drug-carrying lipid nanoparticles were created that incorporate neurotranmitters to help them cross the blood-brain barrier in mice.

Advances in nanoparticles as anticancer drug delivery vector: Need of this century
This review article provides a summary of current advances in the use of nanoparticles (NPs) as anticancer drug-delivery vectors.

Microcapsules for targeted drug delivery to cancer cells
A team of scientists from Peter the Great St. Petersburg Polytechnic University together with their colleagues developed a method of targeted drug delivery to cancer cells.

Improving drug delivery for brain tumor treatment
Despite improvements in drug delivery mechanisms, treating brain tumors has remained challenging.

Nanoparticle orientation offers a way to enhance drug delivery
MIT engineers have shown that they can enhance the performance of drug-delivery nanoparticles by controlling an inherent trait of chemical structures, known as chirality -- the 'handedness' of the structure.

News about drug delivery
Nanocontainer for drugs can have their pitfalls: If they are too heavily loaded, they will only dissolve poorly.

Deflating beach balls and drug delivery
Gwennou Coupier and his colleagues at Grenoble Alps University, Grenoble, France have shown that macroscopic-level models of the properties of microscopic hollow spheres agree very well with theoretical predictions.

Read More: Drug Delivery News and Drug Delivery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.